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Abstract
Background: Sputum Mycobacterium tuberculosis (Mtb) culture is commonly used to assess response to antibiotic treatment
in individuals with pulmonary tuberculosis (TB). Such techniques are constrained by the slow growth rate of Mtb, and more
sensitive methods to monitor Mtb clearance are needed. The goal of this study was to evaluate changes in plasma cytokines
in patients undergoing treatment for TB as a means of identifying candidate host markers associated with microbiologic
response to therapy.
Methods: Twenty-four plasma cytokines/chemokines were measured in 42 individuals diagnosed with active pulmonary TB,
52% were HIV co-infected. Individuals, undergoing a 26-week standard TB treatment, were followed longitudinally over 18
months and measurements were associated with HIV status and rates of sputum culture conversion.
Results: Plasma concentrations of interferon-inducible protein-10 (IP-10) and vascular endothelial growth factor (VEGF) were
significantly reduced upon TB treatment, regardless of HIV status. By the end of treatment, IP-10 concentrations were
significantly lower in HIV negative individuals when compared to HIV-positive individuals (p = 0.02). Moreover, in HIV
negative patients, plasma VEGF concentrations, measured as early as 2-weeks post TB treatment initiation, positively
correlated with the time of sputum conversion (p = 0.0017). No significant changes were observed in other studied immune
mediators.
Conclusions: These data suggest that VEGF plasma concentration, measured during early TB treatment, could represent a
surrogate marker to monitor sputum culture conversion in HIV uninfected individuals.
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Introduction
Mycobacterium tuberculosis (Mtb) infection remains one of theworld’s
major causes of illness and mortality with an estimated 1.4 million
deaths in 2010 [1]. Tuberculosis (TB) has become a global public
health emergency, particularly in developing countries, where more
than 90% of new TB cases and deaths occur [1]. Currently,
monitoringofTB treatment reliesmainlyon sputumcultureor smear
microscopy status. Previous studies have shown an association
between sputum culture conversion within the first 2 months of
conventional TB therapy and non-relapsing cure [2,3]. However,
sputumcultureconversionat2months isnotalwayspredictiveofcure
in individual patients [4,5]. Moreover, sputum culture status can be
more difficult tomonitor in patients withHIV co-infection [6] and is
not applicable in the context of extra-pulmonary disease [7]. This is
particularlyaprobleminareasofhighprevalenceofHIVandMtbco-
infection, suchasSouthAfrica,whereapproximately 60%ofnewTB
cases areHIV seropositive. These limitations emphasize the need for
additional surrogate biomarkers of response to TB treatment. In
addition, the identification and validation of biomarkers that are
predictive of risk of treatment failure or delayed response to TB
therapywould be of value in case-management of patients and could
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contribute to improved outcomes. A number of recent studies have
examined changes in host-specific markers over the course of TB
therapy. For example, anassociationbetween sputum levels of IFN-c
and bacterial clearance has been demonstrated [8] and, while
concentrations of plasma molecules such as soluble urokinase
plasminogen activator receptor (suPAR) [9], soluble intercellular
adhesion molecule type 1 (sICAM) [10], C-reactive protein (CRP)
[11] and cancer antigen 125 (CA-125) [12] have been shown to
correlate with disease severity and to decline with microbiologic
response to treatment.
The goal of this study was to evaluate changes in plasma cytokines
in patients undergoing treatment for TB as a means of identifying
candidate host markers associated with microbiologic response to
therapy. To this end, we measured 24 plasma mediators (endowed
with pro-inflammatory, anti-inflammatory, chemoattractant or
growth functions) before, during and after a 26-week course of
standard TB treatment in 42 individuals, where over half wereHIV-
co-infected. Solublemediator levels and their signature profiles were
analyzed in relation to HIV-status and the time to sputum culture
conversion as an indication of response to TB therapy.
Results
Studied Population
The studied population consisted of 42 individuals diagnosed
with active pulmonary TB, 52% of whom were HIV co-infected
(Tables 1 and 2). All patients presented with either positive
sputum smear microscopy and/or positive culture for Mtb at
enrollment. Drug susceptibility testing was performed at the start
of treatment and resistance to isoniazid or rifampicin was a
criterion for exclusion. There were no statistical differences in age
and body mass index between HIV2 and HIV+ individuals.
Based on chest x-ray examination, HIV infected patients
presented more frequently with minimal cavitary disease when
compared to HIV uninfected patients (p = 0.048). This has been
previously described [13] and could be related to compromised
immune responses induced by HIV infection [14]. All patients
completed the full course of DOTS (Direct Observed Treatment
Short Course). Nine patients (3 HIV negative and 6 HIV positive
subjects) remained sputum culture positive at 26 weeks and
received an additional 26 weeks of treatment with the same drug
regimen. By the end of treatment (26 or 52 weeks of DOTS), all
patients had successfully converted to sputum culture negative.
Studied individuals were divided into 3 groups according to the
time of sputum culture conversion: # 8 weeks, between 12 and 26
weeks and. 26 weeks after the initiation of TB therapy (Tables 1
and 2). Time of culture conversion was defined as the time of the
first negative sputum culture with at least one subsequent negative
culture and no subsequent positive results during the period of
follow-up. No statistical difference was observed in the time of
culture conversion between HIV2 and HIV+ individuals.
Comparison of Baseline Plasma Cytokine Concentrations
between TB+HIV2 and TB+HIV+ Individuals
Using the Luminex assay, we assessed the concentrations of 24
soluble plasma mediators at baseline and during treatment.
Baseline was defined as the plasma sample collected before
initiation of TB treatment. Comparison of baseline plasma
concentrations of each of the 24 cytokines between TB+HIV2
(n = 20) and TB+HIV+ (n = 22) individuals is shown in Figure 1.
Significantly elevated concentrations of IL-4 (p = 0.033), G-CSF
(p = 0.0048), IFN-c (p = 0.0064) and TNF-a (p = 0.0072) and
lower concentrations of IL-12(p70) (p = 0.0054) and IL-17
(p = 0.032) were observed in TB+HIV+ patients as compared to
TB+HIV2 patients. Of note, all reported p-values were adjusted
for multiple comparisons, using a false discovery rate step-down
procedure. The median absolute concentrations and interquartile
range for each cytokine within the 2 groups are detailed in Table
S1. To define if cytokine signature profiles were distinct between
HIV+ and HIV2 individuals, we performed unsupervised
hierarchical clustering and principal component (PCA) analyses
on log-transformed baseline cytokine concentrations. Figure 2A
shows that 73% (16/22) of TB+HIV+ individuals grouped
together, indicating that the majority of HIV infected individuals
shared a specific cytokine expression pattern. The dendrogram
(bottom of Figure 2A) shows the proximity between the different
cytokines, suggesting that cytokines within each sub-cluster
probably share the same origin, common transcriptional regula-
tion and/or common function. These distinct cytokine profile
signatures observed between TB+HIV2 and TB+HIV+ individ-
uals at baseline were further confirmed by PCA, based on the 24
studied cytokines (Figure 2B). PCA enables the discrimination
and visual clustering of two or more classes, where individuals with
similar patterns of cytokine expression are placed next to each
other. As shown in Figure 2B, TB+HIV2 and TB+HIV+
individuals visually segregate on a PCA plot, based on their
baseline plasma cytokine expression patterns.
Overall, these results show that individuals with active TB
disease who are co-infected with HIV show a distinct baseline (pre-
treatment) cytokine expression pattern characterized by elevated
plasma concentrations of TNF-a, G-CSF, IL-4 and IFN-c and
reduced plasma concentrations of IL-12(p70) and IL-17, when
compared to individuals with active TB disease, but who are HIV
uninfected.
Longitudinal Assessment of Cytokine Expression Profiles
Upon and after TB Treatment in TB+HIV2 Individuals
Todefine the impactofa26-weekcourseofTBtherapyoncytokine
expression profiles, we compared the concentrations of cytokines
before (BL: Baseline), during (2, 4, 8, 12 and 26 weeks) and after (52
and 78 weeks) TB therapy. When analyzing the profile of each
cytokineseparately inTB+HIV2 individuals (Figure3),we identified
three distinct response patterns: (i) No significant changes of the
median cytokine concentrations over the studied period. Twelve
cytokines followedthispattern includingIL-4,IL-10,IL-2,IL-5,IL-7,
IL-9, IL-13, G-CSF, IFN-c, MIP-1a, IL-12(p70) and PDGF-BB
(Figure 3A); (ii) Fluctuations in cytokine concentrations over the
studied period (IL-1b, IL-6, IL-1RA, IL-15, IL-17, TNF-a, Eotaxin,
FGF-basic, GM-CSF and MCP-1) (Figure 3B) and (iii) Significant
decrease of the median cytokine levels over time. This latter profile
was observed for IP-10 (chemoattractant) andVEGF (growth factor)
(Figure 3C). Significant declines in IP-10 and VEGF concentrations
during thecourseofTBtreatmentwereconfirmedusing twodifferent
types of statistical analyses: A non-parametric one-way ANOVA
Kruskal-Wallis test, assessing the change in cytokine concentrations
between individual time-points, andrandom-effects linear regression
evaluating the overall trend in log-transformed cytokine concentra-
tions over time, with study participants matched at each time-point.
Using hierarchical clustering and PCA, we found that study
participants did not have specific cytokine signature profiles upon
TB treatment (data not shown), suggesting that large, often
recurrent fluctuations that were observed for certain cytokines
(such as IL-1b, IL-6, IL-15 or IL-17) did not appear to be related
to TB treatment. Of note, when observed, fluctuations in cytokines
concentrations were often detected after 8 weeks of treatment; a
time coinciding with the end of the intensive phase of TB
treatment, when pyrazinamide and ethambutol were discontinued.
These variations did not associate with time to sputum culture
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conversion and were observed in individuals with early (,8weeks)
or late (.26weeks) conversion (Figure 3B). Similar analyses were
performed on the TB+HIV+ arm of the cohort and comparable
results were obtained, where IP-10 and VEGF levels significantly
decreased upon TB therapy (p,0.0001 and p= 0.04, respectively;
Figure S1).
Taken together, these results show that TB treatment leads to a
progressive decrease of IP-10 and VEGF expression levels in both
TB+HIV2 and TB+HIV+ individuals and no significant consis-
tent changes in any others studied cytokines were observed upon
TB therapy.
Comparison of IP-10 and VEGF Down-regulation Rates
Induced by TB Therapy in TB+HIV2 and TB+HIV+
Individuals
To further characterize TB treatment-induced down-regulation
of plasma concentrations of IP-10 and VEGF, we compared the
kinetics of IP-10 and VEGF levels between TB+HIV2 and
TB+HIV+ individuals. In both groups, IP-10 and VEGF down-
regulation followed a one-phase decay curve (Figure 4A). Upon
TB therapy, the rate of decline in IP-10 level, between baseline
and 26-week measurements, was significantly steeper in
TB+HIV2 patients when compared with TB+HIV+ patients
(p = 0.02); where the median fold changes in IP-10 concentrations
were 0.24 (IQR: 0.08–0.37) in TB+HIV2 subjects and 0.41 (IQR:
0.23–0.67) in TB+HIV+ subjects (Figure 4B). Of note, fold
changes in IP-10 concentrations between TB+HIV2 and
TB+HIV+ individuals were also significantly different between
baseline and 2, 4, 52 and 78 weeks post TB therapy initiation
[p= 0.03, p= 0.019, p = 0.012 and p=0.045, respectively (data
not shown)]. In contrast, the rate of decline in VEGF concentra-
tions were comparable for both groups (Figure 4A), with no
differences being apparent in the median fold changes between
baseline and 26 week for either patient group (Figure 4B).
These data show that IP-10 down-regulation, in response to TB
treatment, is more pronounced in TB+HIV2 patients when
compared to TB+HIV+ patients, suggesting that sustained viral
replication possibly contributes to elevated concentrations of IP-10
in HIV infected TB patients.
Relationship between Cytokine Concentrations and Time
to Sputum Culture Conversion
We next analyzed if any measured plasma factor could be
potential candidates as surrogate markers for sputum culture
conversion. Cytokine concentrations, at each time point, were
correlated with the time to sputum culture conversion in
Table 1. Clinical characteristics of HIV2TB+ individuals (n = 20).
Clinical presentation of TB Outcome
HIV2TB+ Gender
Age at enrolment
(years)
Culture at
enrolment Xraya BMI
Culture at 26
weeks
Time of Conversion
(wks)b
TB122 F 27 + 3 22.03 2 6
TB036 M 46 + 2 18.29 2 8
TB117 M 42 + 2 17.80 2 8
TB131 M 44 + 2 19.61 2 8
TB132 M 30 + 2 21.08 2 8
TB039 M 56 + 2 21.34 2 12
TB048 M 40 + 3 16.96 2 12
TB095 M 48 + 3 18.13 2 12
TB112 F 41 + 2 19.66 2 12
TB124 M 62 + 3 26.77 2 12
TB130 M 22 + 3 18.56 2 12
TB088 M 21 + 2 18.78 2 24
TB096 M 59 + 3 16.22 2 24
TB114 M 26 + 2 17.10 2 24
TB129 M 32 + 2 25.10 2 24
TB097 M 52 + 2 17.51 2 24
TB125 M 30 + 2 19.47 + 36
TB069 M 37 + 3 17.01 + 52
TB090 M 35 + 2 18.56 2 52
TB031 F 50 + 2 24.12 + 52
Average (M) 86% 40 (+) 100% 19.7 (+) 15% 21.1
Range [21–62] [16.22–26.77] [6–52]
M: Male, F: Female.
a: 1: No cavities ; 2: cavities ,4 cm ; 3: cavities $4 cm.
BMI: Body mass index.
nd: not determined.
b: The time of conversion is defined as the first analyzed time point where culture was negative and remained negative at all following time points. Studied individuals
were divided into 3 groups according to the time of sputum culture conversion: # 8 weeks, between 12 and 26 weeks and. 26 weeks after the initiation of TB therapy.
doi:10.1371/journal.pone.0036886.t001
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TB+HIV2 and TB+HIV+ individuals. Figure 5 shows that
plasma VEGF concentrations, measured at 2 weeks after initiation
of TB treatment, was positively associated with the time of sputum
culture conversion in TB+HIV2 individuals (r = 0.72, p = 0.0017,
Figure 5A). Positive associations were also observed between
VEGF concentrations measured at 4, 12, and 26 weeks post TB
treatment and time of sputum culture conversion [p= 0.0032,
p = 0.043 and p= 0.0036, respectively (data not shown)]. Of note,
no association was found between baseline VEGF concentrations
and the time of culture sputum conversion. These associations
were not observed in the TB+HIV+ group at any time point
(Figure 5B). Moreover, no associations were observed between
any other cytokine measured and time of culture sputum
conversion. These data suggest that plasma VEGF concentrations,
measured as early as 2 weeks after the initiation of TB treatment,
could predict bacterial clearance in HIV negative individuals and
could be used as a prospective marker of time to sputum culture
conversion.
Discussion
In this report, we monitored the plasma cytokine environment
during TB therapy and for 1 year afterwards in 42 individuals with
active TB, 52% of whom were HIV positive. Since HIV infection
is known to induce pro-inflammatory cytokine production, it is
conceivable that HIV co-infected patients could possess distinct
cytokine profiles, when compared with patients with TB only
[15,16]. Indeed we show, at baseline, that TB+HIV+ individuals
displayed a different cytokine expression pattern when compared
to TB+HIV2 individuals, and co-infection was characterized by
elevated IL-4, G-CSF, IFN-c and TNF-a concentrations and
decreased IL-12(p70) and IL-17 levels. This suggests that HIV co-
infection could affect TB immune responses by causing dysregu-
lation in cytokine production. Elevated TNF-a, in addition to
playing a key role in granuloma formation [17], could also favour
granulomatous necrosis increasing lung tissue damage [18,19] and
reduced IL-17 production could limit the recruitment of CD4+ T
cells into the lungs [20]. These data further emphasize the
importance of considering concomitant infections when
monitoring immune responses during TB, as they could
considerably alter anti-bacterial immune responses.
Longitudinal assessment of the plasma cytokine profile showed
that amongst the 24 mediators studied, only IP-10 and VEGF
concentrations significantly decreased during the course of TB
therapy in both TB+HIV2 and TB+HIV+ individuals. We had
Table 2. Clinical characteristics of HIV+TB+ individuals (n = 22).
HIV+TB+ Gender
Age at enrolment
(years)
Culture at
enrolment Xraya BMI
Culture at 26
weeks
Time of Conversion
(wks)b
TBH041 M 32 + 2 18.37 2 4
TBH068 M 44 + 2 15.05 2 4
TBH084 M 39 + 2 19.03 2 4
TBH089 F 29 + 2 19.77 2 4
TBH037 F 51 + 1 20.26 2 6
TBH028 M 33 + 2 16.29 2 8
TBH080 M 24 + nd 18.64 2 8
TBH113 F 52 + 2 19.81 2 8
TBH045 M 58 + 3 16.59 2 12
TBH079 F 23 + 2 19.29 2 12
TBH123 M 36 + 2 20.28 2 12
TBH033 F 39 + 2 nd 2 24
TBH034 M 33 + 2 nd 2 24
TBH035 M 44 + 2 nd 2 24
TBH093 F 21 + 1 21.93 2 24
TBH094 F 21 + 3 35.70 2 24
TBH074 M 36 + 2 17.63 + 36
TBH087 M 30 + 2 19.05 + 36
TBH081 M 31 + 2 28.01 + 52
TBH083 M 28 nd 2 nd + 52
TBH135 M 41 + 3 nd + 52
TBH091 F 38 + 1 17.91 + 52
Average (M) 64% 35.6 (+) 100% 20.21 (+) 27% 21.9
Range [21–58] [15.05–35.70] [4–52]
M: Male, F: Female.
a: 1: No cavities; 2: cavities ,4 cm; 3: cavities $4 cm.
BMI: Body mass index.
nd: not determined.
b: The time of conversion is defined as the first analyzed time point where culture was negative and remained negative at all following time points. Studied individuals
were divided into 3 groups according to the time of sputum culture conversion: # 8 weeks, between 12 and 26 weeks and. 26 weeks after the initiation of TB therapy.
doi:10.1371/journal.pone.0036886.t002
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Figure 1. Comparison of baseline expression levels of soluble plasma mediators between TB+HIV2 and TB+HIV+ individuals. (A)
Mediators endowed with pro- and anti-inflammatory functions. (B) Mediators endowed with pleiotropic, chemoattractant and growth functions.
Results are expressed as pg/ml of plasma. Open circles represent TB+HIV2 subjects (n = 20) and black circles correspond to TB+HIV+ subjects (n = 22).
Dotted lines represent the average limit of detection for all cytokines. Statistical comparisons have been performed using non-parametric Mann-
Whitney U test and corrected for multiple comparisons using a false discovery rate (FDR) step down procedure.
doi:10.1371/journal.pone.0036886.g001
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expected that plasma concentrations of other cytokines (such as
IFN-c or TNF-a) would change in response to treatment-induced
bacillary clearance, as bacillary load has been associated with
changes in the immune response during TB treatment. For
instance, it has been reported that IFN-c levels in sputum closely
correlated with mycobacterial clearance [8]. Moreover, Bekker et
al. showed that initiation of TB treatment led to a transitory
increase in TNF-a levels, while IFN-c and IL-6 levels were
progressively reduced, in individuals with severe TB [21]. The
apparent stable cytokine expression levels observed for these
molecules in the present study could reflect the compartmentalized
production of cytokines, where cytokines are more likely to
accumulate and decline at the site of infection in the lung.
Our longitudinal data revealed that some pro-inflammatory
cytokines (such as IL-1b, IL-6, IL-15, and TNF-a) as well as IL-
1Ra and MCP-1 displayed a fluctuating profile later during
treatment. For most of the studied individuals, the occurrence of
these fluctuations appeared to coincide with the transition from
the intensive TB treatment phase to the continuation phase, when
pyrazinamide and ethambutol were discontinued, or at the end of
Figure 2. Expression profiles of baseline plasma cytokines in TB+HIV2 and TB+HIV+ individuals. (A) Two-dimensional unsupervised
hierarchical clustering of baseline cytokine profiles in TB+HIV2 (n = 20) and TB+HIV+ (n = 22) subjects. The normalized values for each cytokine are
depicted according to the color scale, where red and green represent expression above and below the median, respectively. (B) Three-dimensional
representation of principal component analysis (PCA) of HIV2 (red) and HIV+ (green) individuals. Each dot represents one subject based on values of
all 23 cytokines studied. The percentage of variances is depicted on the 3 axes. The distance in space between each dot represents the relatedness
between each individual.
doi:10.1371/journal.pone.0036886.g002
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Figure 3. Longitudinal assessment of plasma cytokine expression levels before, during and after TB therapy in TB+HIV2
individuals. The concentration of each cytokine has been measured at baseline, 2, 4, 8, 12, 26, 52, 78 weeks after the initiation of a 26- week
treatment period. Individuals who presented with sputum conversion at #8 weeks are depicted in red, individual who presented with sputum
culture conversion between 12 and 26 weeks are depicted in blue and individuals where sputum culture conversion occurred after 26 weeks of TB
therapy are shown in green. (A) Plasma cytokine levels (IL-2, IL-5, IL-13, G-CSF, IL-12, PDGF-BB, IL-7, IL-9, IFN-c, MIP-1b, IL-4 and IL-10) showing no
significant change overtime. (B) Plasma cytokine levels (IL-1RA, IL-6, Eotaxin, FGF-basic, IL-17, TNF-a, GM-CSF, MCP-1, IL-1b and IL-15) fluctuating
overtime. (C) Plasma cytokines (IP-10 and VEGF) presenting significant changes over time. Each dot represents one individual (n = 20). Results are
expressed as pg/ml of plasma. Dotted lines represent the limit of detection for each cytokine. Gray shaded box (on the first graph) represents the
duration of TB therapy; dark gray box depicts the intensive phase of treatment, including rifampicin, isoniazid, pyrazinamide and ethambutol, while
light gray box corresponds to the second phase of treatment with rifampicin and isoniazid. Statistical analyses were performed using non-parametric
one-way ANOVA Kruskal-Wallis Tests (*: p,0.05, **: p,0.01, ***: P,0.001). Numerical p-values, reflecting the overall changes in IP-10 and VEGF
expression levels, have been determined using random-effects linear regression. The x-axis (time after the initiation of treatment in weeks) has been
logged to allow better visualization of cytokine expression levels at early time points.
doi:10.1371/journal.pone.0036886.g003
Figure 4. Comparison of the decrease rate of IP-10 and VEGF in TB+HIV2 and TB+HIV+ individuals upon TB therapy. (A) Longitudinal
plasma IP-10 and VEGF concentrations before, during and after TB therapy in TB+HIV2 (Red) and TB+HIV+ (Black) individuals. Values were log-
transformed. Median values with 95% CI for TB+HIV2 (n = 20) and TB+ HIV+ (n = 22) individuals are depicted in red and black, respectively. A shaded
grey box represents the duration of TB therapy. Statistical analyses were performed using random-effects linear regression. (B) Comparison of fold-
changes in plasma IP-10 and VEGF concentrations between baseline and 26-week measurements (end of TB therapy) in TB+HIV2 and TB+HIV+
subjects. Each dot represents one individual. Open circles correspond to individuals who presented with sputum conversion at #8 weeks, closed
circles correspond to individuals who presented with sputum culture conversion between 12 and 26 weeks after TB therapy initiation and crosses
identify individuals where sputum culture conversion occurred after 26 weeks post treatment. Doted lines depict 50% and 80% reduction of cytokine
expression levels. Statistical analyses were performed using non-parametric Mann-Whitney U test.
doi:10.1371/journal.pone.0036886.g004
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treatment. Although we do not have a substantiated explanation
for this phenomenon, the timing of these observations suggests that
alterations in drug regimens (2 months and 6 months of standard
DOTS) may lead to changes in the regulation of some immune
mediators. Evidence to support this interpretation was reported in
a recent study demonstrating that pyrazinamide treatment can
affect cytokine production in J774 cells and bone marrow-derived
mouse macrophages and dendritic cells [22]. In addition, a
Figure 5. Correlation between plasma VEGF concentrations at 2 weeks post TB therapy initiation and time to sputum culture
conversion. (A) TB+HIV2 individuals; (B) TB+HIV+ individuals. VEGF concentration values were log-transformed. Statistical associations were
performed by a two-tailed non-parametric Spearman rank correlation.
doi:10.1371/journal.pone.0036886.g005
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number of studies have described the immunomodulatory effects
of other antibiotics, in particular the quinolones and macrolides
[23,24].
Our data also show that, in response to TB therapy, only IP-10
and VEGF levels showed statistically significant changes in plasma
in both TB+HIV2 and TB+HIV+ infected individuals. IP-10 is a
chemoattractant, facilitating the recruitment and trafficking of
monocytes, T cells, NK cells and dendritic cells. IP-10 is produced
by a variety of cells including neutrophils, monocytes, endothelial
cells and fibroblasts in response to IFN-c and TNF-a [25,26,27].
Thus IP-10 expression levels may reflect the extent of the ongoing
pro-inflammatory immune response. Elevated expression of IP-10
has been described in both active TB [28,29,30,31] and HIV
infection [32,33,34]. It is commonly accepted that plasma IP-10
concentration is a reflection of TB disease activity [35,36,37].
Moreover, plasma IP-10 levels have been shown to decrease upon
successful treatment [35,38]. Hence, it has been speculated that
IP-10 could be a better prediction marker of TB infection as
compared to IFN-c or TNF-a [28,30,36,39]. The present data
confirm that plasma IP-10 concentrations decrease significantly
upon efficient TB therapy in both TB+HIV2 and TB+HIV+
individuals and show that the rate of IP-10 down-regulation was
lower in HIV co-infected subjects. It is plausible that ongoing HIV
replication would lead to sustained immune inflammation and
production of IFN-c and TNF-a, fueling IP-10 production. Taken
together, our results suggest that although IP-10 is not a specific
marker for Mtb infection [26], monitoring IP-10 levels in active
TB patients could be a valuable marker for clinical response and
treatment outcome.
VEGF, endowed with potent angiogenic, lymphangiogenic and
vascular permeability activities in endothelial cells, is up-regulated
in response to tissue inflammation, hypoxia and pro-inflammatory
cytokines (reviewed in [40,41]). Thus, VEGF may influence
leukocyte trafficking by playing a role in blood and lymphatic
vessel function during inflammation [42]. Indeed, VEGF is
chemoattractant for monocytes [40] and its over-expression in
mouse models leads to abundant angiogenesis and inflammation
[43]. Serum VEGF and angioprotein-2 levels have been shown to
be associated with the severity of systemic inflammation in patients
with inflammatory lung disease [44]. Although the specific role of
VEGF in the pathogenesis of TB is unclear, it has been suggested
that VEGF may participate in the neovascularization in granu-
lomatous tissue [45], favoring the progression of chronic
inflammation in association with pulmonary damage. In active
TB, elevated plasma VEGF levels have been reported in several
publications [46,47,48]; activated macrophages are the most likely
source of VEGF in TB lesions [48]. In the present report, we
observed that plasma VEGF concentrations decrease upon TB
therapy with comparable rates in both TB+HIV2 and TB+HIV+
individuals. Importantly, in HIV uninfected subjects, plasma
VEGF concentrations, measured as early as 2 weeks after
treatment initiation, positively associated with the time of culture
sputum conversion. This suggests that as the bacillary load is
controlled in the lungs, inflammation-induced VEGF production
is reduced. Indeed, angiogenesis and chronic inflammation have
been described as inter-dependent events [49]. The lack of
association between VEGF and the time to sputum conversion in
TB+HIV+ individuals may be due to chronic HIV-driven hyper-
immune activation.
In conclusion, treatment-induced Mtb clearance, routinely
assessed by sputum culture conversion is to date the principal
measure of TB treatment success. However, more sensitive and
rapid predictive assays are needed to improve clinical manage-
ment of TB patients as emphasized in several publications
[27,50,51,52,53]. Our data show that measurement of plasma
IP-10 and VEGF concentrations could be a valuable adjunct to
monitor TB treatment, and suggest that persistently elevated
VEGF and/or IP-10 levels may reflect inefficient therapy or lack
of treatment compliance. Further analyses in a greater number of
individuals with appropriate control populations will be needed to
validate the usefulness of this approach.
Materials and Methods
Studied Participants
Participants were recruited in two outpatient pulmonary TB
treatment facilities in Durban (South Africa) between August 2000
and November 2001. Participants were eligible when $18 years of
age and consenting to HIV pre- and post-test counseling and
testing. Drug susceptibility testing was performed at the time of TB
therapy initiation and individuals presenting with resistance to
isoniazid or rifampicin were excluded from the study. Diagnosis of
active pulmonary TB was based on symptoms, roentgenographic
evaluation and epidemiologic history. All included patients
presented with either positive sputum smear microscopy and/or
positive culture for Mtb. Numerical score were used for grading
Chest x-ray severity, where (1) corresponds to individuals
presenting no cavities; (2) subjects with cavities , 4 cm and (3)
individuals with cavities $ 4 cm. Plasma and sputum samples
were collected at enrollment, 2, 4, 8, 12, 26, 52 and 78 weeks after
the initiation of TB therapy. We studied a subset of 42 individuals
who had samples collected at all time points. At the time of
screening, 20 subjects were HIV-negative and 22 subjects tested
positive for HIV. This study took place prior to the ARV roll-out
program and patients did not receive any anti-retroviral therapy at
that time. All HIV-infected individuals were viremic at the time of
enrollment (median viral load: 18,860 copies/ml [IQR: 13,189–
48,039]) with low CD4 counts (median: 282 cells/mm3 [IQR:
177–448]). Standard directly observed TB treatment (DOT) was
started after enrolment and was in accordance with the South-
African Guidelines for the management of TB [31]. All individuals
were administered 4-drug fixed-dose combination tablets (rifam-
picin, isoniazid, pyrazinamide, ethambutol) for 8 weeks, followed
by a 16 week-course of 2-drug fixed dose combination tablets
(rifampicin, isoniazid). The ethics committees of Nelson Mandela
Medical School and Witwatersrand University approved the initial
study, with subsequent approval from the IRB of the University of
Medicine and Dentistry of New Jersey, for the cytokine
measurements on the plasma samples. All the subjects provided
written informed consent for participation in this study.
Bacteriological Assessment of Sputum Acid-fast-bacillus
Smear and Sputum Culture
The diagnosis of TB was based on the detection of acid-fast
bacilli under direct fluorescent microscopy and confirmed by
culture on Lowenstein-Jensen media or MGIT culture system
(Becton-Dickinson, Baltimore, USA) for baseline isolates of
Mycobacterium tuberculosis and to determine TB outcomes at 8, 12,
26, 52 and 78 weeks. We defined culture conversion as the first
negative sputum culture with at least one subsequent negative
culture and no subsequent positive results.
Multiplex Cytokine and Chemokine Analysis
Samples were kept at 280uC until use. Frozen plasma samples
were quickly defrosted, spun down to remove clots. Samples were
then passed through a Costar Spin-X Centrifuge Tube, 0.22 mm
nylon filter, and diluted 1:4 with sample diluents provided in the
Luminex kit. Cytokine levels were measured by multiplex bead
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array technology according to manufacturer’s instructions
(Bulletin#10014905; Bio-Rad, Hercules, USA) and read on a
luminometer (Luminex, Austin, USA). Bio-Plex Pro assays enabled
us to quantify multiple protein biomarkers in a single well, using
12.5 ml of plasma. The use of magnetic (MagPlexH) beads allowed
us to automate wash steps on a Bio-Plex Pro wash station offering
greater reproducibility compared to vacuum filtration. Twenty-
seven plasma mediators were evaluated. The panel included
interleukin-1 beta (IL-1b), IL-1 receptor antagonist (IL-1RA), IL-
2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12(p70), IL-13, IL-
15, IL-17, IFN-c (Interferon gamma), tumor necrosis factor alpha
(TNF-a), macrophage inflammatory protein 1 alpha (MIP-1a),
macrophage inflammatory protein 1 beta (MIP-1b), granulocyte
colony stimulating factor (G-CSF), granulocyte macrophage
colony stimulating factor (GM-CSF), eotaxin, fibroblast growth
factor basic (FGF-basic), monocyte chemotactic protein (MCP-1),
regulated upon activation normal T cell expressed and secreted
(RANTES), IFN-c-induced protein (IP-10), platelet derived
growth factor BB (PDGF-BB) and vascular endothelial growth
factor (VEGF). Of note, IL-8, RANTES and MIP-1a were
excluded from the analysis, as measurements for these markers
were outside the linear detection range of the assay.
Unsupervised Hierarchical Clustering, Principal
Component Analysis (PCA) and Statistical Analysis
Unsupervised hierarchical clustering of cytokine secretion of
HIV positive and HIV negative individuals and generation of a
heat map as well as PCA analysis were done using the Qlucore
Omics Explorer software (Qlucore, Lund, Sweden). Statistical
analyses were performed using GraphPad Prism version 5.0
(GraphPad Software, San Diego, USA) and STATATM version 10
(StataCorp, Texas, USA). Distribution of all variables was assessed
by Shapiro-Wilk and Shapiro-Francia tests. Baseline comparisons
of cytokine concentrations were performed using non-parametric
Mann-Whitney U test and adjusted for multiple comparisons using
false discovery rate step-down procedures [54]. For longitudinal
measurements, soluble mediator concentrations were log-trans-
formed and analyzed using one-way ANOVA Kruskal-Wallis test
and Random-effects linear regression.
Supporting Information
Figure S1 Longitudinal assessment of plasma cytokine
concentrations before, during and after the course of
TB therapy in TB+HIV+ individuals. The concentration of
each cytokine has been measured at baseline, 2, 4, 8, 12, 26, 52, 78
weeks after the initiation of a 26- week treatment period. (A)
cytokines showing no significant change overtime. (B) cytokines
fluctuating overtime. (C) cytokines showing significant change
overtime. Statistical analyses were performed using non-paramet-
ric one-way ANOVA Kruskal-Wallis Tests (*: p,0.05, **:
p,0.01, ***: P,0.001). Numerical p-values, reflecting the overall
changes in IP-10 and VEGF expression levels, have been
determined using random-effects linear regression. The x-axis
(time after the initiation of treatment in weeks) has been logged to
allow better visualization of cytokine expression levels at early time
points.
(TIF)
Table S1 Baseline median plasma concentrations of
cytokines in TB+HIV+ and TB+HIV2 individuals. Statis-
tical comparisons have been performed using non-parametric
Mann-Whitney U test and corrected for multiple comparisons
using a false discovery rate (FDR) step down procedure.
Interquartile Ranges (IQR) are shown in brackets.
(TIF)
Acknowledgments
We would like to acknowledge the participants, TBRU staff and the South-
African Department of Health.
Author Contributions
Conceived and designed the experiments: DF CG GK. Performed the
experiments: BPP CM. Analyzed the data: CR LR KR. Contributed
reagents/materials/analysis tools: RR TM. Wrote the paper: CR LR GW
CG GK.
References
1. WHO (March 2010) Tuberculosis, Fact sheet No 104 p.
2. Holtz TH, Sternberg M, Kammerer S, Laserson KF, Riekstina V, et al. (2006)
Time to sputum culture conversion in multidrug-resistant tuberculosis:
predictors and relationship to treatment outcome. Ann Intern Med 144:
650–659.
3. Wallis RS, Wang C, Doherty M, Onyebujoh P, Vahedi M, et al. (2010)
Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect
Diseases 10: 70–71.
4. Benator D, Bhattacharya M, Bozeman L, Burman W, Cantazaro A, et al. (2002)
Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a
week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative
patients: a randomised clinical trial. Lancet 360: 528–534.
5. Johnson JL, Hadad DJ, Dietze R, Maciel EL, Sewali B, et al. (2009) Shortening
treatment in adults with noncavitary tuberculosis and 2-month culture
conversion. Am J Respir Crit Care Med 180: 558–563.
6. Sharma SK, Mohan A, Kadhiravan T (2005) HIV2TB co-infection:
epidemiology, diagnosis and management. Indian J Med Res 121: 550–567.
7. Sharma SK, Mohan A (2004) Extra-pulmonary tuberculosis. Indian J Med Res
120: 317–353.
8. Ribeiro-Rodrigues R, Resende Co T, Johnson JL, Ribeiro F, Palaci M, et al.
(2002) Sputum cytokine levels in patients with pulmonary tuberculosis as early
markers of mycobacterial clearance. Clin Diagn Lab Immunol 9: 818–823.
9. Eugen-Olsen J, Gustafson P, Sidenius N, Fischer TK, Parner J, et al. (2002) The
serum level of soluble urokinase receptor is elevated in tuberculosis patients and
predicts mortality during treatment: a community study from Guinea-Bissau.
Int J Tuberc Lung Dis 6: 686–692.
10. Demir T, Yalcinoz C, Keskinel I, Demiroz F, Yildirim N (2002) sICAM-1 as a
serum marker in the diagnosis and follow-up of treatment of pulmonary
tuberculosis. Int J Tuberc Lung Dis 6: 155–159.
11. Bajaj G, Rattan A, Ahmad P (1989) Prognostic value of ‘C’ reactive protein in
tuberculosis. Indian Pediatr 26: 1010–1013.
12. Huang WC, Tseng CW, Chang KM, Hsu JY, Chen JH, et al. (2011) Usefulness
of Tumor Marker CA-125 Serum Levels for the Follow-Up of Therapeutic
Responses in Tuberculosis Patients with and without Serositis. Jpn J Infect Dis
64: 367–372.
13. Aliyu MH, Salihu HM, Ratard R (2003) HIV infection and sputum-culture
conversion in patients diagnosed with Mycobacterium tuberculosis: a popula-
tion-based study. Wien Klin Wochenschr 115: 340–346.
14. Rose RM (1991) Immunology of the lung in HIV infection: the pathophysiologic
basis for the development of tuberculosis in the AIDS setting. Bull Int Union
Tuberc Lung Dis 66: 15–20.
15. Subramanyam S, Hanna LE, Venkatesan P, Sankaran K, Narayanan PR, et al.
(2004) HIV alters plasma and M. tuberculosis-induced cytokine production in
patients with tuberculosis. J Interferon Cytokine Res 24: 101–106.
16. Gordeuk VR, Moyo VM, Nouraie M, Gangaidzo IT, Murphree NL, et al.
(2009) Circulating cytokines in pulmonary tuberculosis according to HIV status
and dietary iron content. Int J Tuberc Lung Dis 13: 1267–1273.
17. Roach DR, Bean AG, Demangel C, France MP, Briscoe H, et al. (2002) TNF
regulates chemokine induction essential for cell recruitment, granuloma
formation, and clearance of mycobacterial infection. J Immunol 168:
4620–4627.
18. Bezuidenhout J, Roberts T, Muller L, van Helden P, Walzl G (2009) Pleural
tuberculosis in patients with early HIV infection is associated with increased
TNF-alpha expression and necrosis in granulomas. PLoS One 4: e4228.
19. Bekker LG, Moreira AL, Bergtold A, Freeman S, Ryffel B, et al. (2000)
Immunopathologic effects of tumor necrosis factor alpha in murine mycobac-
terial infection are dose dependent. Infect Immun 68: 6954–6961.
Plasma Cytokine Levels upon TB Treatment
PLoS ONE | www.plosone.org 11 May 2012 | Volume 7 | Issue 5 | e36886
20. Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, et al. (2007) IL-
23 and IL-17 in the establishment of protective pulmonary CD4+ T cell
responses after vaccination and during Mycobacterium tuberculosis challenge.
Nat Immunol 8: 369–377.
21. Bekker LG, Maartens G, Steyn L, Kaplan G (1998) Selective increase in plasma
tumor necrosis factor-alpha and concomitant clinical deterioration after
initiating therapy in patients with severe tuberculosis. J Infect Dis 178: 580–584.
22. Mendez S, Traslavina R, Hinchman M, Huang L, Green P, et al. (2009) The
antituberculosis drug pyrazinamide affects the course of cutaneous leishmaniasis
in vivo and increases activation of macrophages and dendritic cells. Antimicrob
Agents Chemother 53: 5114–5121.
23. Dalhoff A, Shalit I (1996) Immunomodulatory effects of quinolones. Lancet
Infect Dis 3: 359–371.
24. Morikawa K, Watabe H, Araake M, Morikawa S (1996) Modulatory effect of
antibiotics on cytokine production by human monocytes in vitro. Antimicrob
Agents Chemother 40: 1366–1370.
25. Kapplan G, Luster AD, Handcock G, Cohn ZA (1987) The expression of a
gamma interferon-induced protein (IP-10) in delayed immune responses in
human skin. J exp Med 166: 1098–1108.
26. Liu M, Guo S, Hibbert JM, Jain V, Singh N, et al. (2011) CXCL10/IP-10 in
infectious diseases pathogenesis and potential therapeutic implications. Cytokine
Growth Factor Rev 22: 121–130.
27. John SH, Kenneth J, Gandhe AS (2011) Host biomarkers of clinical relevance in
tuberculosis: review of gene and protein expression studies. Biomarkers.
28. Whittaker E, Gordon A, Kampmann B (2008) Is IP-10 a better biomarker for
active and latent tuberculosis in children than IFNgamma? PLoS One 3: e3901.
29. Cannas A, Calvo L, Chiacchio T, Cuzzi G, Vanini V, et al. (2010) IP-10
detection in urine is associated with lung diseases. BMC Infect Dis 10: 333–341.
30. Goletti D, Raja A, Syed Ahamed Kabeer B, Rodrigues C, Sodha A, et al. (2010)
Is IP-10 an accurate marker for detecting M. tuberculosis-specific response in
HIV-infected persons? PLoS One 5: e12577.
31. SA TUBERCULOSIS STRATEGIC PLAN FOR SOUTH AFRICA (2007–
2011) Department of Health Republic of South Africa.
32. Gay C, Dibben O, Anderson JA, Stacey A, Mayo AJ, et al. (2011) Cross-
sectional detection of acute HIV infection: timing of transmission, inflammation
and antiretroviral therapy. PLoS One 6: e19617.
33. Lane BR, King SR, Bock PJ, Strieter RM, Coffey MJ, et al. (2003) The C-X-C
chemokine IP-10 stimulates HIV-1 replication. Virology 307: 122–134.
34. Keating SM, Golub ET, Nowicki M, Young M, Anastos K, et al. (2011) The
effect of HIV infection and HAART on inflammatory biomarkers in a
population-based cohort of US women. Aids.
35. Azzurri A, Sow OY, Amedei A, Bah B, Diallo S, et al. (2005) IFN-gamma-
inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring
inflammation and disease activity in Mycobacterium tuberculosis infection.
Microbes Infect 7: 1–8.
36. Supriya P, Chandrasekaran P, Das SD (2008) Diagnostic utility of interferon-
gamma-induced protein of 10 kDa (IP-10) in tuberculous pleurisy. Diagn
Microbiol Infect Dis 62: 186–192.
37. Ruhwald M, Bjerregaard-Andersen M, Rabna P, Eugen-Olsen J, Ravn P (2009)
IP-10, MCP-1, MCP-2, MCP-3, and IL-1RA hold promise as biomarkers for
infection with M. tuberculosis in a whole blood based T-cell assay. BMC Res
Notes 2: 19.
38. Djoba Siawaya JF, Beyers N, van Helden P, Walzl G (2009) Differential cytokine
secretion and early treatment response in patients with pulmonary tuberculosis.
Clin Exp Immunol 156: 69–77.
39. Kabeer BSA, Raja A, Raman B, Thangaraj S, Leportier M, et al. (2011) IP-10
response to RD1 antigens might be a useful biomarker for monitoring
tuberculosis therapy. BMC Infect Dis 11: 135–144.
40. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its
receptors. Nat Med 9: 669–676.
41. Koch S, Tugues S, Li X, Gualandi L, Claesson-Welsh L (2011) Signal
transduction by vascular endothelial growth factor receptors. Biochem J 437:
169–183.
42. Tammela T, Petrova TV, Alitalo K (2005) Molecular lymphangiogenesis: new
players. Trends Cell Biol 15: 434–441.
43. Xia YP, Li B, Hylton D, Detmar M, Yancopoulos GD, et al. (2003) Transgenic
delivery of VEGF to the mouse skin leads to an inflammatory condition
resembling human psoriasis. Blood 102: 161–168.
44. Park HY, Hahm CR, Jeon K, Koh WJ, Suh GY, et al. (2012) Serum vascular
endothelial growth factor and angiopoietin-2 are associated with the severity of
systemic inflammation rather than the presence of hemoptysis in patients with
inflammatory lung disease. Yonsei Med J 52: 369–376.
45. Sakaguchi I, Ikeda N, Nakayama M, Kato Y, Yano I, et al. (2000) Trehalose
6,6’-dimycolate (Cord factor) enhances neovascularization through vascular
endothelial growth factor production by neutrophils and macrophages. Infect
Immun 68: 2043–2052.
46. Alatas F, Alatas O, Metintas M, Ozarslan A, Erginel S, et al. (2004) Vascular
endothelial growth factor levels in active pulmonary tuberculosis. Chest 125:
2156–2159.
47. Abe Y, Nakamura M, Oshika Y, Hatanaka H, Tokunaga T, et al. (2001) Serum
levels of vascular endothelial growth factor and cavity formation in active
pulmonary tuberculosis. Respiration 68: 496–500.
48. Matsuyama W, Hashiguchi T, Matsumuro K, Iwami F, Hirotsu Y, et al. (2000)
Increased serum level of vascular endothelial growth factor in pulmonary
tuberculosis. Am J Respir Crit Care Med 162: 1120–1122.
49. Costa C, Incio J, Soares R (2007) Angiogenesis and chronic inflammation: cause
or consequence? Angiogenesis 10: 149–166.
50. Jacobsen M, Repsilber D, Gutschmidt A, Neher A, Feldmann K, et al. (2007)
Candidate biomarkers for discrimination between infection and disease caused
by Mycobacterium tuberculosis. J Mol Med (Berl) 85: 613–621.
51. Walzl G, Ronacher K, Djoba Siawaya JF, Dockrell HM (2008) Biomarkers for
TB treatment response: challenges and future strategies. J Infect 57: 103–109.
52. Wallis R, Johnson JL (2005) The Role of Surrogate Markers in the Clinical
Evaluation of Anti-tuberculous Chemotherapy. Curr Med Chem - Anti-Infective
Agents 4: 1–8.
53. Wallis RS, Pai M, Menzies D, Doherty TM, Walzl G, et al. (2010) Biomarkers
and diagnostics for tuberculosis: progress, needs, and translation into practice.
Lancet 375: 1920–1937.
54. Columb MO, Sagadai S (2006) Multiple comparisons. Current Anaesthesia &
Critical Care 17: 233–236.
Plasma Cytokine Levels upon TB Treatment
PLoS ONE | www.plosone.org 12 May 2012 | Volume 7 | Issue 5 | e36886
